疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2600人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1721064, encodeId=72691e2106405, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, objectType=article, longId=216279, objectId=b8872162e982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8872162e982, replyNumber=0, likeNumber=89, createdTime=2021-12-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8872162e982, moduleTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8872162e982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721097, encodeId=dccf1e2109703, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JEADV:新型固定剂量钙泊三烯和倍他米松乳膏局部治疗斑块型银屑病的疗效和安全性, objectType=article, longId=219036, objectId=1886219036cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1886219036cf, replyNumber=0, likeNumber=108, createdTime=2022-07-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1886219036cf, moduleTitle=JEADV:新型固定剂量钙泊三烯和倍他米松乳膏局部治疗斑块型银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1886219036cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721032, encodeId=67541e21032d9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=100, createdTime=2021-09-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721132, encodeId=b3171e21132dd, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=63, createdTime=2021-12-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721113, encodeId=5da51e21113d2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, objectType=article, longId=220567, objectId=10c022056e58, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10c022056e58, replyNumber=0, likeNumber=70, createdTime=2022-08-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10c022056e58, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10c022056e58)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721056, encodeId=72b21e2105604, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, objectType=article, longId=214609, objectId=4c4421460961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c4421460961, replyNumber=0, likeNumber=86, createdTime=2022-03-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c4421460961, moduleTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c4421460961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721030, encodeId=849e1e2103056, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=84, createdTime=2022-02-02, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lasers Med Sci：非热氮等离子体与长脉冲Nd:YAG激光在手部嫩肤中的疗效和安全性 , objectType=article, longId=723712, objectId=fb69e23712be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb69e23712be, replyNumber=0, likeNumber=83, createdTime=2023-02-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb69e23712be, moduleTitle=Lasers Med Sci：非热氮等离子体与长脉冲Nd:YAG激光在手部嫩肤中的疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb69e23712be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721067, encodeId=7f961e210672e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, objectType=article, longId=216579, objectId=57b22165e959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b22165e959, replyNumber=0, likeNumber=90, createdTime=2021-11-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b22165e959, moduleTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b22165e959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721114, encodeId=568e1e2111423, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性, objectType=article, longId=220654, objectId=94b8220654c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b8220654c0, replyNumber=0, likeNumber=84, createdTime=2022-10-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b8220654c0, moduleTitle=J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b8220654c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721116, encodeId=cdb61e21116e3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性, objectType=article, longId=220636, objectId=883e22063602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=883e22063602, replyNumber=0, likeNumber=76, createdTime=2022-09-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=883e22063602, moduleTitle=P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=883e22063602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721043, encodeId=9eaf1e2104337, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, objectType=article, longId=213341, objectId=9b0321334101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0321334101, replyNumber=0, likeNumber=119, createdTime=2022-02-07, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0321334101, moduleTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0321334101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721078, encodeId=cd3f1e210784a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Respir Med：肺动脉高压患者连续服用Selonsertib的疗效和安全性, objectType=article, longId=217067, objectId=4dc921e067d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc921e067d9, replyNumber=0, likeNumber=75, createdTime=2022-01-20, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc921e067d9, moduleTitle=Lancet Respir Med：肺动脉高压患者连续服用Selonsertib的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dc921e067d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721159, encodeId=4e441e21159f8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, objectType=article, longId=295133, objectId=e466295133ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e466295133ba, replyNumber=0, likeNumber=101, createdTime=2022-09-10, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e466295133ba, moduleTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e466295133ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721151, encodeId=3d131e21151a4, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, objectType=article, longId=292954, objectId=a2d3292954c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d3292954c0, replyNumber=0, likeNumber=48, createdTime=2022-01-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d3292954c0, moduleTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d3292954c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721169, encodeId=cd871e2116930, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JEADV：富马酸二甲酯与传统银屑病治疗相比的疗效和安全性, objectType=article, longId=300138, objectId=f94530013854, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94530013854, replyNumber=0, likeNumber=83, createdTime=2022-10-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94530013854, moduleTitle=JEADV：富马酸二甲酯与传统银屑病治疗相比的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f94530013854)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721102, encodeId=e14f1e21102c6, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验, objectType=article, longId=219213, objectId=3deb219213a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3deb219213a1, replyNumber=0, likeNumber=84, createdTime=2022-02-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3deb219213a1, moduleTitle=Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3deb219213a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721099, encodeId=29bc1e21099b4, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, objectType=article, longId=219105, objectId=f9f621910501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9f621910501, replyNumber=0, likeNumber=49, createdTime=2021-12-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9f621910501, moduleTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9f621910501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721021, encodeId=16b91e21021e5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, objectType=article, longId=211682, objectId=d50921168225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50921168225, replyNumber=0, likeNumber=89, createdTime=2022-03-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50921168225, moduleTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50921168225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721011, encodeId=51f51e21011e6, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, objectType=article, longId=210899, objectId=70f82108996e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70f82108996e, replyNumber=0, likeNumber=68, createdTime=2022-03-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70f82108996e, moduleTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70f82108996e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性

2021-12-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JEADV:新型固定剂量钙泊三烯和倍他米松乳膏局部治疗斑块型银屑病的疗效和安全性

2022-07-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2021-09-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2021-12-15

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究

2022-08-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性

2022-03-01

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2022-02-02

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lasers Med Sci：非热氮等离子体与长脉冲Nd:YAG激光在手部嫩肤中的疗效和安全性

2023-02-13

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性

2021-11-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：特瑞普利单抗（Toripalimab）联合IMRT治疗复发鼻咽癌（rNPC）的疗效和安全性

2022-10-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性

2022-09-04

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果

2022-02-07

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Respir Med：肺动脉高压患者连续服用Selonsertib的疗效和安全性

2022-01-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性

2022-09-10

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性

2022-01-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JEADV：富马酸二甲酯与传统银屑病治疗相比的疗效和安全性

2022-10-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验

2022-02-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性

2021-12-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果

2022-03-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性

2022-03-29

科室
- - 订阅+
  - 更多科室
工具
服务